Ambicare News

Ambicare Health demonstrates it’s revolutionary device to key European practitioners in Monaco

The Ambulight PDT by Ambicare Health was officially unveiled today (12 March) to key European practitioners at The European Society for Photodynamic Therapy ('Society' or 'Euro-PDT') 10th Annual Congress in Monte-Carlo, Monaco.

The Euro-PDT is one of Europe's most prestigious conferences for new developments and research in all aspects of PDT for skin diseases, the Ambulight PDT will be showcased to members of the Society from all across Europe.

Having received CE Mark approval last year enabling active marketing of the device in Europe, the conference will give Dr Andrew McNeill, Director and Principle Scientist of Ambicare Health the opportunity to present the company's research for the first time on 'Ambulatory light sources for PDT'.

Ambulight PDT is the world's first skin cancer treatment using a small disposable light emitting sticking plaster worn by the patient. This is used in conjunction with a prescribed pharmaceutical, for the treatment of non-melanoma skin cancer. This plaster delivers PDT treatment directly to the skin lesion site.

Ambulight PDT offers healthcare providers the opportunity to transform patient care by making PDT more accessible and enabling patients to continue with their normal daily routine when undergoing PDT treatment. Pilot clinical trials have also indicated this treatment method has lower pain than conventional techniques whilst still obtaining an equivalent outcome.

Ian Muirhead, CEO of Ambicare Health said, "The Ambulight PDT is the most advanced ambulatory PDT device to treat non-melanoma skin cancer to be developed to date. We believe that it is the future for this kind of treatment; Ambulight PDT will reduce costs for the healthcare provider by freeing up hospital day patient beds or cubicles and improve patient care by allowing them to continue with their normal daily lives during treatment.

"The Euro-PDT congress is an important platform for us to demonstrate the technology and research that has been years in the development and to further emphasis the benefits this revolutionary product could bring to a global market."

For further information or to confirm times available for interview please contact:


Buchanan Communications

Diane Stewart (dianes@buchanan.uk.com)
0131 226 6150
Carrie Clement (carriec@buchanan.uk.com)
0131 226 4427

Interview/Photo Opportunity: Chief Executive Officer Ian Muirhead will be available for interview during the course of the two-day conference with the opportunity to photograph the Ambulight PDT, the world's first skin cancer treatment using a small disposable light emitting sticking plaster worn by the patient.

Telephone interviews will also be available before and following the conference on request.

Date: 12 - 13th March 2010
Time: To be arranged
Venue: Monte Carlo Bay Hotel, Monte Carlo, Monaco

 

Notes to Editors:

In Europe PDT is regularly the first line of treatment recommended for non melanoma skin cancer. It is a two-step process involving the application of a pharmaceutical cream which creates a photosensitive daughter compound, followed by controlled exposure to a selective light source which activates the light sensitive chemical and destroys the diseased cells.

The alternative treatment methods to PDT are surgery, use of topical creams and cryotherapy. Each of these can be painful, irritate the skin, leave scarring and can be highly stressful for the patient. PDT treatment is less invasive than surgery and avoids the scarring associated with surgical removal of the lesion which can often require an in-patient hospital stay. Ambulight PDT gives healthcare providers the opportunity to shift treatment from hospitals to primary care such as GP surgeries or office based dermatologists.



12th March 2010